Why Pfizer's Post-COVID Future Looks Brighter Than Ever
It's been a rough few years to be a (NYSE: PFE) shareholder. Shares of the big pharma stock are down about 61% from a peak they set in late 2021. That year, the company's COVID-19 vaccine, Comirnaty, racked up $36.8 billion in sales.
In the first half of 2025, Comirnaty sales came in at just $945 million. Sales of Paxlovid, an antiviral treatment for COVID-19, fell 60% year over year to $918 million. Despite sinking demand for Comirnaty and Paxlovid, Pfizer's post-COVID future looks bright.
Image source: Getty Images.
Source Fool.com
Pfizer Inc. Aktie
22,03 €
-0,07 %
Leichte Buy-Präferenz bei der Pfizer Inc. Aktie.
Ein Kursziel von 27 € für Pfizer Inc. signalisiert eine potenzielle Steigerung von über 20% gegenüber dem aktuellen Kurs von 22.03 €.
